Document Detail

Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension.
MedLine Citation:
PMID:  19617273     Owner:  NLM     Status:  MEDLINE    
Combining an angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin II receptor blocker (ARB) lowers blood pressure (BP) by 4/3 mmHg compared to either agent alone, although this additive effect may be abolished with maximal monotherapy dosing. The recent ONTARGET study showed no reduction in primary outcomes when an ACE-I-ARB combination was compared to an ACE-I alone, despite 2.4/1.4 mmHg lower BP in the former group. In proteinuric chronic kidney disease, an ACE-I-ARB combination reduces proteinuria and disease progression more than monotherapy, but the ONTARGET study showed an increase in renal endpoints in the combined group. Aliskiren offers a novel approach to renin-angiotensin system (RAS) inhibition. As monotherapy in hypertension, aliskiren is of similar efficacy to thiazides, calcium channel blockers and ARBs. In combination with other RAS inhibitors at maximal dosage aliskiren has a small synergistic effect on BP (additional 4/2 mmHg reduction). Early data suggest a role for aliskiren in preventing end-organ damage but, considering the ONTARGET results with an ACE-I-ARB combination, outcome studies are needed before the use of aliskiren can be recommended in combination with other RAS inhibitors. As monotherapy, aliskiren should probably be reserved for use as an alternative to ACE-Is or ARBs, where these are ineffective or poorly tolerated.
Timothy W R Doulton; Graham A MacGregor
Related Documents :
11786523 - Mice lacking endothelial angiotensin-converting enzyme have a normal blood pressure.
2405803 - Efficacy, safety, and quality-of-life assessment of captopril antihypertensive therapy ...
19807493 - Long-term social costs of hypertension.
Publication Detail:
Type:  Journal Article     Date:  2009-07-17
Journal Detail:
Title:  Journal of the renin-angiotensin-aldosterone system : JRAAS     Volume:  10     ISSN:  1752-8976     ISO Abbreviation:  J Renin Angiotensin Aldosterone Syst     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-12-22     Completed Date:  2010-02-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100971636     Medline TA:  J Renin Angiotensin Aldosterone Syst     Country:  England    
Other Details:
Languages:  eng     Pagination:  185-9     Citation Subset:  IM    
Blood Pressure Unit, Department of Cardiac and Vascular Sciences, St. George's, University of London, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amides / therapeutic use*
Angiotensin II Type 1 Receptor Blockers / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Antihypertensive Agents / therapeutic use*
Drug Therapy, Combination
Fumarates / therapeutic use*
Hypertension / drug therapy*
Renin / antagonists & inhibitors*
Renin-Angiotensin System / drug effects
Reg. No./Substance:
0/Amides; 0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Fumarates; 0/aliskiren; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Angiotensin II does not influence expression of sarcoplasmic reticulum Ca2 + ATPase in atrial myocyt...
Next Document:  Atrial fibrillation in primary aldosteronism.